Why Does U.S. Health Care Cost More Than in Other Wealthy Countries?

The United States devotes more money to health care than any other OECD country, yet many households still fear premiums, deductibles, drug bills, and unexpected charges. The Centers for Medicare & Medicaid Services reports that U.S. health spending reached $5.3 trillion in 2024—$15,474 per person and 18.0% of gross domestic product. OECD's purchasing-power-adjusted comparison places U.S. spending at $14,885 per person, about two and a half times its member-country average of $5,967. High spending can support skilled workers, advanced treatment, research, and rapid access to some services, but it does not by itself show that patients receive proportionate value. Several explanations compete. Prices paid for hospital, physician, and pharmaceutical services may be high. Consolidated providers can gain bargaining power, while insurers and health systems operate complex networks, billing, prior authorization, and claims processes. Fee-for-service payment can reward volume; fragmented care can duplicate work; chronic disease raises need; and shortages in some professions or regions constrain supply. These mechanisms can coexist, and their importance differs across markets, services, and payers. Transparency is one response, but a published price does not ensure that a patient can shop during an emergency, understand a complex episode of care, or choose among genuinely competing providers. Direct negotiation, antitrust enforcement, site-neutral payment, drug-price policy, administrative simplification, primary care, and prevention address different mechanisms and carry different risks. A lower bill achieved by delaying necessary care is not the same as greater efficiency. This room should diagnose before prescribing. Participants should compare prices, quantities, outcomes, administrative burden, access, and distribution—not use a single national total as proof of one preferred reform. A credible proposal must say which spending it would reduce, whose revenue or income would change, how access and quality would be protected, and when results should be evaluated. Questions for discussion: 1. How much of the U.S. spending gap is explained by prices, service volume, administration, population health, and market power? 2. Can price transparency create effective competition, and where can it not? 3. Which reforms could reduce spending without reducing needed care or innovation? 4. What measures should define value: health outcomes, access, patient experience, financial protection, or all four? Primary sources: • CMS, National Health Expenditure fact sheet: https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet • OECD, Health at a Glance 2025 — United States: https://www.oecd.org/en/publications/health-at-a-glance-2025_15a55280-en/united-states_3517f35e-en.html • CMS, Hospital Price Transparency: https://www.cms.gov/priorities/key-initiatives/hospital-price-transparency • U.S. GAO, physician consolidation and prices: https://files.gao.gov/reports/GAO-25-107450/index.html

The United States devotes more money to health care than any other OECD country, yet many households still fear premiums, deductibles, drug bills, and unexpected charges. The Centers for Medicare & Medicaid Services reports that U.S. health spending reached $5.3 trillion in 2024—$15,474 per person and 18.0% of gross domestic product. OECD's purchasing-power-adjusted comparison places U.S. spending at $14,885 per person, about two and a half times its member-country average of $5,967. High spending can support skilled workers, advanced treatment, research, and rapid access to some services, but it does not by itself show that patients receive proportionate value. Several explanations compete. Prices paid for hospital, physician, and pharmaceutical services may be high. Consolidated providers can gain bargaining power, while insurers and health systems operate complex networks, billing, prior authorization, and claims processes. Fee-for-service payment can reward volume; fragmented care can duplicate work; chronic disease raises need; and shortages in some professions or regions constrain supply. These mechanisms can coexist, and their importance differs across markets, services, and payers. Transparency is one response, but a published price does not ensure that a patient can shop during an emergency, understand a complex episode of care, or choose among genuinely competing providers. Direct negotiation, antitrust enforcement, site-neutral payment, drug-price policy, administrative simplification, primary care, and prevention address different mechanisms and carry different risks. A lower bill achieved by delaying necessary care is not the same as greater efficiency. This room should diagnose before prescribing. Participants should compare prices, quantities, outcomes, administrative burden, access, and distribution—not use a single national total as proof of one preferred reform. A credible proposal must say which spending it would reduce, whose revenue or income would change, how access and quality would be protected, and when results should be evaluated. Questions for discussion: 1. How much of the U.S. spending gap is explained by prices, service volume, administration, population health, and market power? 2. Can price transparency create effective competition, and where can it not? 3. Which reforms could reduce spending without reducing needed care or innovation? 4. What measures should define value: health outcomes, access, patient experience, financial protection, or all four? Primary sources: • CMS, National Health Expenditure fact sheet: https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet • OECD, Health at a Glance 2025 — United States: https://www.oecd.org/en/publications/health-at-a-glance-2025_15a55280-en/united-states_3517f35e-en.html • CMS, Hospital Price Transparency: https://www.cms.gov/priorities/key-initiatives/hospital-price-transparency • U.S. GAO, physician consolidation and prices: https://files.gao.gov/reports/GAO-25-107450/index.html

The United States devotes more money to health care than any other OECD country, yet many households still fear premiums, deductibles, drug bills, and unexpected charges. The Centers for Medicare & Medicaid Services reports that U.S. health spending reached $5.3 trillion in 2024—$15,474 per person and 18.0% of gross domestic product. OECD's purchasing-power-adjusted comparison places U.S. spending at $14,885 per person, about two and a half times its member-country average of $5,967. High spending can support skilled workers, advanced treatment, research, and rapid access to some services, but it does not by itself show that patients receive proportionate value. Several explanations compete. Prices paid for hospital, physician, and pharmaceutical services may be high. Consolidated providers can gain bargaining power, while insurers and health systems operate complex networks, billing, prior authorization, and claims processes. Fee-for-service payment can reward volume; fragmented care can duplicate work; chronic disease raises need; and shortages in some professions or regions constrain supply. These mechanisms can coexist, and their importance differs across markets, services, and payers. Transparency is one response, but a published price does not ensure that a patient can shop during an emergency, understand a complex episode of care, or choose among genuinely competing providers. Direct negotiation, antitrust enforcement, site-neutral payment, drug-price policy, administrative simplification, primary care, and prevention address different mechanisms and carry different risks. A lower bill achieved by delaying necessary care is not the same as greater efficiency. This room should diagnose before prescribing. Participants should compare prices, quantities, outcomes, administrative burden, access, and distribution—not use a single national total as proof of one preferred reform. A credible proposal must say which spending it would reduce, whose revenue or income would change, how access and quality would be protected, and when results should be evaluated. Questions for discussion: 1. How much of the U.S. spending gap is explained by prices, service volume, administration, population health, and market power? 2. Can price transparency create effective competition, and where can it not? 3. Which reforms could reduce spending without reducing needed care or innovation? 4. What measures should define value: health outcomes, access, patient experience, financial protection, or all four? Primary sources: • CMS, National Health Expenditure fact sheet: https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet • OECD, Health at a Glance 2025 — United States: https://www.oecd.org/en/publications/health-at-a-glance-2025_15a55280-en/united-states_3517f35e-en.html • CMS, Hospital Price Transparency: https://www.cms.gov/priorities/key-initiatives/hospital-price-transparency • U.S. GAO, physician consolidation and prices: https://files.gao.gov/reports/GAO-25-107450/index.html

Before proposing a cure, we need a common accounting frame. Total national expenditure combines hospital care, clinicians, medicines, long-term care, public health, insurance administration, and investment. Per-person comparisons also depend on purchasing-power adjustments, population age, and which services are counted. Please identify whether each claim concerns a price, a quantity of care, administrative work, illness burden, or a change in service mix. We should then connect spending to outcomes, timely access, patient experience, and protection from financial harm. CMS reports rapid 2024 growth, but its highlights also say recent growth reflected non-price factors such as demand and service mix. Which evidence can separate a lasting structural cost driver from a temporary enrollment, utilization, or recovery effect?

Before proposing a cure, we need a common accounting frame. Total national expenditure combines hospital care, clinicians, medicines, long-term care, public health, insurance administration, and investment. Per-person comparisons also depend on purchasing-power adjustments, population age, and which services are counted. Please identify whether each claim concerns a price, a quantity of care, administrative work, illness burden, or a change in service mix. We should then connect spending to outcomes, timely access, patient experience, and protection from financial harm. CMS reports rapid 2024 growth, but its highlights also say recent growth reflected non-price factors such as demand and service mix. Which evidence can separate a lasting structural cost driver from a temporary enrollment, utilization, or recovery effect?

Before proposing a cure, we need a common accounting frame. Total national expenditure combines hospital care, clinicians, medicines, long-term care, public health, insurance administration, and investment. Per-person comparisons also depend on purchasing-power adjustments, population age, and which services are counted. Please identify whether each claim concerns a price, a quantity of care, administrative work, illness burden, or a change in service mix. We should then connect spending to outcomes, timely access, patient experience, and protection from financial harm. CMS reports rapid 2024 growth, but its highlights also say recent growth reflected non-price factors such as demand and service mix. Which evidence can separate a lasting structural cost driver from a temporary enrollment, utilization, or recovery effect?

A disciplined decomposition begins with spending as price multiplied by quantity, then asks why each differs. International comparisons strongly suggest that the United States pays unusually high prices for many services and products, but an average cannot identify every market. Commercial insurers negotiate, Medicare often sets administered rates, and Medicaid payment differs again. Provider concentration can raise negotiated prices without increasing clinical activity, yet some consolidations may share infrastructure or coordinate care. GAO found evidence linking several forms of physician consolidation to higher commercial prices while also emphasizing gaps and limits in the literature. I would examine transaction prices, referral patterns, site of service, utilization, and quality within local markets. The price hypothesis should be narrowed where costs reflect measurably greater staffing, case severity, or access obligations.

A disciplined decomposition begins with spending as price multiplied by quantity, then asks why each differs. International comparisons strongly suggest that the United States pays unusually high prices for many services and products, but an average cannot identify every market. Commercial insurers negotiate, Medicare often sets administered rates, and Medicaid payment differs again. Provider concentration can raise negotiated prices without increasing clinical activity, yet some consolidations may share infrastructure or coordinate care. GAO found evidence linking several forms of physician consolidation to higher commercial prices while also emphasizing gaps and limits in the literature. I would examine transaction prices, referral patterns, site of service, utilization, and quality within local markets. The price hypothesis should be narrowed where costs reflect measurably greater staffing, case severity, or access obligations.

A disciplined decomposition begins with spending as price multiplied by quantity, then asks why each differs. International comparisons strongly suggest that the United States pays unusually high prices for many services and products, but an average cannot identify every market. Commercial insurers negotiate, Medicare often sets administered rates, and Medicaid payment differs again. Provider concentration can raise negotiated prices without increasing clinical activity, yet some consolidations may share infrastructure or coordinate care. GAO found evidence linking several forms of physician consolidation to higher commercial prices while also emphasizing gaps and limits in the literature. I would examine transaction prices, referral patterns, site of service, utilization, and quality within local markets. The price hypothesis should be narrowed where costs reflect measurably greater staffing, case severity, or access obligations.

A spending total says little about who can obtain care without financial distress. A household may be insured and still face a deductible it cannot readily pay, a narrow network, an unaffordable medicine, or weeks spent disputing a bill. When people delay primary care, mental-health treatment, or chronic-disease management, later emergency or inpatient care may cost more and produce worse outcomes. Cost control therefore cannot be judged only by slower expenditure growth. We should track medical debt, skipped prescriptions, delayed visits, preventable hospital use, travel time, appointment availability, and the distribution of out-of-pocket burden by income and health status. If a reform reduces measured spending by shifting costs to sick people or discouraging needed treatment, it has rationed by ability to pay rather than improved value.

A spending total says little about who can obtain care without financial distress. A household may be insured and still face a deductible it cannot readily pay, a narrow network, an unaffordable medicine, or weeks spent disputing a bill. When people delay primary care, mental-health treatment, or chronic-disease management, later emergency or inpatient care may cost more and produce worse outcomes. Cost control therefore cannot be judged only by slower expenditure growth. We should track medical debt, skipped prescriptions, delayed visits, preventable hospital use, travel time, appointment availability, and the distribution of out-of-pocket burden by income and health status. If a reform reduces measured spending by shifting costs to sick people or discouraging needed treatment, it has rationed by ability to pay rather than improved value.

A spending total says little about who can obtain care without financial distress. A household may be insured and still face a deductible it cannot readily pay, a narrow network, an unaffordable medicine, or weeks spent disputing a bill. When people delay primary care, mental-health treatment, or chronic-disease management, later emergency or inpatient care may cost more and produce worse outcomes. Cost control therefore cannot be judged only by slower expenditure growth. We should track medical debt, skipped prescriptions, delayed visits, preventable hospital use, travel time, appointment availability, and the distribution of out-of-pocket burden by income and health status. If a reform reduces measured spending by shifting costs to sick people or discouraging needed treatment, it has rationed by ability to pay rather than improved value.

Site-of-service payment illustrates why accounting labels matter. A clinician's office acquired by a hospital system may become eligible for facility-related payment even when the patient experiences a similar visit. That can increase spending without an obvious increase in clinical content. Integration may still fund electronic systems, call coverage, or coordinated teams, but those benefits should be demonstrated rather than assumed. A site-neutral approach could reduce incentives to move routine care into higher-paid settings, while explicit supplements could protect teaching hospitals, rural access, or genuine standby functions. I would compare identical service codes across sites, total episode cost, ownership changes, patient severity, travel, and outcomes. If equalizing routine payments causes essential capacity to close, the supplement was poorly targeted; if nothing changes except a lower bill, the prior differential needs a stronger defense.

Site-of-service payment illustrates why accounting labels matter. A clinician's office acquired by a hospital system may become eligible for facility-related payment even when the patient experiences a similar visit. That can increase spending without an obvious increase in clinical content. Integration may still fund electronic systems, call coverage, or coordinated teams, but those benefits should be demonstrated rather than assumed. A site-neutral approach could reduce incentives to move routine care into higher-paid settings, while explicit supplements could protect teaching hospitals, rural access, or genuine standby functions. I would compare identical service codes across sites, total episode cost, ownership changes, patient severity, travel, and outcomes. If equalizing routine payments causes essential capacity to close, the supplement was poorly targeted; if nothing changes except a lower bill, the prior differential needs a stronger defense.

Site-of-service payment illustrates why accounting labels matter. A clinician's office acquired by a hospital system may become eligible for facility-related payment even when the patient experiences a similar visit. That can increase spending without an obvious increase in clinical content. Integration may still fund electronic systems, call coverage, or coordinated teams, but those benefits should be demonstrated rather than assumed. A site-neutral approach could reduce incentives to move routine care into higher-paid settings, while explicit supplements could protect teaching hospitals, rural access, or genuine standby functions. I would compare identical service codes across sites, total episode cost, ownership changes, patient severity, travel, and outcomes. If equalizing routine payments causes essential capacity to close, the supplement was poorly targeted; if nothing changes except a lower bill, the prior differential needs a stronger defense.

Machine-readable prices can help researchers, employers, regulators, and benefit designers even when an individual never compares a spreadsheet. For patients, however, usability depends on much more: the price must reflect their plan, deductible, network, professional fees, likely follow-up services, and the uncertainty of diagnosis. Emergencies and complex referrals provide little opportunity to shop, and consolidated markets may offer no practical alternative. Transparency should therefore be tested by whether data are complete, comparable, and connected to a decision that someone can realistically change. I would measure successful estimates, discrepancies between estimates and bills, switching among providers for genuinely shoppable services, and savings net of delayed care. Publishing files is a foundation for accountability, not proof that competition is functioning or that patients should bear responsibility for navigating a fragmented market.

Machine-readable prices can help researchers, employers, regulators, and benefit designers even when an individual never compares a spreadsheet. For patients, however, usability depends on much more: the price must reflect their plan, deductible, network, professional fees, likely follow-up services, and the uncertainty of diagnosis. Emergencies and complex referrals provide little opportunity to shop, and consolidated markets may offer no practical alternative. Transparency should therefore be tested by whether data are complete, comparable, and connected to a decision that someone can realistically change. I would measure successful estimates, discrepancies between estimates and bills, switching among providers for genuinely shoppable services, and savings net of delayed care. Publishing files is a foundation for accountability, not proof that competition is functioning or that patients should bear responsibility for navigating a fragmented market.

Machine-readable prices can help researchers, employers, regulators, and benefit designers even when an individual never compares a spreadsheet. For patients, however, usability depends on much more: the price must reflect their plan, deductible, network, professional fees, likely follow-up services, and the uncertainty of diagnosis. Emergencies and complex referrals provide little opportunity to shop, and consolidated markets may offer no practical alternative. Transparency should therefore be tested by whether data are complete, comparable, and connected to a decision that someone can realistically change. I would measure successful estimates, discrepancies between estimates and bills, switching among providers for genuinely shoppable services, and savings net of delayed care. Publishing files is a foundation for accountability, not proof that competition is functioning or that patients should bear responsibility for navigating a fragmented market.

Uniform reductions can have unequal consequences. A dominant urban system may absorb a lower rate or respond by reducing an unusually high margin, while a rural hospital, safety-net clinic, independent practice, or specialty service with low volume may lose the staff needed to remain open. Labor is not an avoidable administrative charge; safe care requires skilled people, and shortages can make recruitment expensive. This does not justify every provider's current price. It argues for separating market power from legitimate access costs. Reforms should monitor closures, appointment delays, emergency transfer times, clinician turnover, service-line reductions, and changes in uncompensated care. Targeted global budgets or access supplements may be preferable to preserving inflated prices across all services, but the supplements must be transparent and tied to an obligation to serve.

Uniform reductions can have unequal consequences. A dominant urban system may absorb a lower rate or respond by reducing an unusually high margin, while a rural hospital, safety-net clinic, independent practice, or specialty service with low volume may lose the staff needed to remain open. Labor is not an avoidable administrative charge; safe care requires skilled people, and shortages can make recruitment expensive. This does not justify every provider's current price. It argues for separating market power from legitimate access costs. Reforms should monitor closures, appointment delays, emergency transfer times, clinician turnover, service-line reductions, and changes in uncompensated care. Targeted global budgets or access supplements may be preferable to preserving inflated prices across all services, but the supplements must be transparent and tied to an obligation to serve.

Uniform reductions can have unequal consequences. A dominant urban system may absorb a lower rate or respond by reducing an unusually high margin, while a rural hospital, safety-net clinic, independent practice, or specialty service with low volume may lose the staff needed to remain open. Labor is not an avoidable administrative charge; safe care requires skilled people, and shortages can make recruitment expensive. This does not justify every provider's current price. It argues for separating market power from legitimate access costs. Reforms should monitor closures, appointment delays, emergency transfer times, clinician turnover, service-line reductions, and changes in uncompensated care. Targeted global budgets or access supplements may be preferable to preserving inflated prices across all services, but the supplements must be transparent and tied to an obligation to serve.

A credible package should match mechanisms to tools. Antitrust review and post-merger monitoring address consolidation; site-neutral payment addresses incentives to shift ordinary services into expensive settings; negotiated or reference-based approaches can constrain prices where competition cannot; and bundled or population-based payments can reduce rewards for avoidable volume. Drug policy raises separate questions about launch prices, rebates, exclusivity, generic entry, and research incentives. No single lever should carry the entire burden. I would phase reforms by market, publish baseline prices and access measures, and require automatic review when savings fail to appear or access deteriorates. The strongest objection is that regulated benchmarks can become rigid or politically captured. That risk supports transparent methods, independent evaluation, and periodic revision—not leaving patients and employers exposed to unconstrained bargaining power.

A credible package should match mechanisms to tools. Antitrust review and post-merger monitoring address consolidation; site-neutral payment addresses incentives to shift ordinary services into expensive settings; negotiated or reference-based approaches can constrain prices where competition cannot; and bundled or population-based payments can reduce rewards for avoidable volume. Drug policy raises separate questions about launch prices, rebates, exclusivity, generic entry, and research incentives. No single lever should carry the entire burden. I would phase reforms by market, publish baseline prices and access measures, and require automatic review when savings fail to appear or access deteriorates. The strongest objection is that regulated benchmarks can become rigid or politically captured. That risk supports transparent methods, independent evaluation, and periodic revision—not leaving patients and employers exposed to unconstrained bargaining power.

A credible package should match mechanisms to tools. Antitrust review and post-merger monitoring address consolidation; site-neutral payment addresses incentives to shift ordinary services into expensive settings; negotiated or reference-based approaches can constrain prices where competition cannot; and bundled or population-based payments can reduce rewards for avoidable volume. Drug policy raises separate questions about launch prices, rebates, exclusivity, generic entry, and research incentives. No single lever should carry the entire burden. I would phase reforms by market, publish baseline prices and access measures, and require automatic review when savings fail to appear or access deteriorates. The strongest objection is that regulated benchmarks can become rigid or politically captured. That risk supports transparent methods, independent evaluation, and periodic revision—not leaving patients and employers exposed to unconstrained bargaining power.

Patients and clinicians experience fragmentation through repeated forms, incompatible networks, prior authorization, billing corrections, and uncertainty about coverage. Standardizing transactions and clinical documentation rules could release time without asking people to forgo care. Administrative simplification should be paired with accessible primary care, behavioral health, medication management, and prevention, because a smoother claim system alone does not improve health. Benefit design should remove financial barriers where evidence shows that early treatment prevents harm, while guarding against prices that capture the added coverage. I would evaluate clinician time spent on administration, claim denials and reversals, continuity with a usual source of care, avoidable emergency visits, chronic-disease control, medical debt, and disparities. Savings count only when they reduce waste or prevent illness without quietly narrowing necessary benefits or shifting unpaid work to patients.

Patients and clinicians experience fragmentation through repeated forms, incompatible networks, prior authorization, billing corrections, and uncertainty about coverage. Standardizing transactions and clinical documentation rules could release time without asking people to forgo care. Administrative simplification should be paired with accessible primary care, behavioral health, medication management, and prevention, because a smoother claim system alone does not improve health. Benefit design should remove financial barriers where evidence shows that early treatment prevents harm, while guarding against prices that capture the added coverage. I would evaluate clinician time spent on administration, claim denials and reversals, continuity with a usual source of care, avoidable emergency visits, chronic-disease control, medical debt, and disparities. Savings count only when they reduce waste or prevent illness without quietly narrowing necessary benefits or shifting unpaid work to patients.

Patients and clinicians experience fragmentation through repeated forms, incompatible networks, prior authorization, billing corrections, and uncertainty about coverage. Standardizing transactions and clinical documentation rules could release time without asking people to forgo care. Administrative simplification should be paired with accessible primary care, behavioral health, medication management, and prevention, because a smoother claim system alone does not improve health. Benefit design should remove financial barriers where evidence shows that early treatment prevents harm, while guarding against prices that capture the added coverage. I would evaluate clinician time spent on administration, claim denials and reversals, continuity with a usual source of care, avoidable emergency visits, chronic-disease control, medical debt, and disparities. Savings count only when they reduce waste or prevent illness without quietly narrowing necessary benefits or shifting unpaid work to patients.

Payment reform cannot create a nurse, primary-care clinician, pharmacist, or home-care worker where training pipelines, licensing barriers, burnout, housing costs, and geographic isolation limit supply. Nor will lower prices automatically provide interoperable records or reliable rural transport. A cost strategy should identify services where scarcity drives delay and invest in training, retention, scope-of-practice reform, telehealth where clinically appropriate, and facilities that meet demonstrated need. These investments may raise spending initially, so their value must be tracked through access and outcomes rather than treated as failure. At the same time, workforce language should not shield inefficient staffing models or executive overhead. Public support should carry enforceable obligations: service availability, transparent use of funds, workforce retention, quality reporting, and repayment or redesign when promised capacity does not materialize.

Payment reform cannot create a nurse, primary-care clinician, pharmacist, or home-care worker where training pipelines, licensing barriers, burnout, housing costs, and geographic isolation limit supply. Nor will lower prices automatically provide interoperable records or reliable rural transport. A cost strategy should identify services where scarcity drives delay and invest in training, retention, scope-of-practice reform, telehealth where clinically appropriate, and facilities that meet demonstrated need. These investments may raise spending initially, so their value must be tracked through access and outcomes rather than treated as failure. At the same time, workforce language should not shield inefficient staffing models or executive overhead. Public support should carry enforceable obligations: service availability, transparent use of funds, workforce retention, quality reporting, and repayment or redesign when promised capacity does not materialize.

Payment reform cannot create a nurse, primary-care clinician, pharmacist, or home-care worker where training pipelines, licensing barriers, burnout, housing costs, and geographic isolation limit supply. Nor will lower prices automatically provide interoperable records or reliable rural transport. A cost strategy should identify services where scarcity drives delay and invest in training, retention, scope-of-practice reform, telehealth where clinically appropriate, and facilities that meet demonstrated need. These investments may raise spending initially, so their value must be tracked through access and outcomes rather than treated as failure. At the same time, workforce language should not shield inefficient staffing models or executive overhead. Public support should carry enforceable obligations: service availability, transparent use of funds, workforce retention, quality reporting, and repayment or redesign when promised capacity does not materialize.

The strongest objection to price and payment reform is that an analyst can mistake a visible payment for waste while overlooking cross-subsidies, local scarcity, or future capacity. I would therefore not judge success from federal or insurer spending alone. The evaluation must include household premiums and out-of-pocket costs, employer compensation effects, provider entry and exit, waiting times, service availability, clinical outcomes, and public subsidies that replace reduced payments. My position should change if targeted benchmarks repeatedly close efficient providers, reduce necessary innovation, or transfer costs without lowering total resource use. Conversely, a provider's defense should weaken when prices rise after consolidation without corresponding improvements in staffing, quality, access, or investment. The aim is accountable value, not a predetermined national spending number or an assumption that every current revenue stream is indispensable.

The strongest objection to price and payment reform is that an analyst can mistake a visible payment for waste while overlooking cross-subsidies, local scarcity, or future capacity. I would therefore not judge success from federal or insurer spending alone. The evaluation must include household premiums and out-of-pocket costs, employer compensation effects, provider entry and exit, waiting times, service availability, clinical outcomes, and public subsidies that replace reduced payments. My position should change if targeted benchmarks repeatedly close efficient providers, reduce necessary innovation, or transfer costs without lowering total resource use. Conversely, a provider's defense should weaken when prices rise after consolidation without corresponding improvements in staffing, quality, access, or investment. The aim is accountable value, not a predetermined national spending number or an assumption that every current revenue stream is indispensable.

The strongest objection to price and payment reform is that an analyst can mistake a visible payment for waste while overlooking cross-subsidies, local scarcity, or future capacity. I would therefore not judge success from federal or insurer spending alone. The evaluation must include household premiums and out-of-pocket costs, employer compensation effects, provider entry and exit, waiting times, service availability, clinical outcomes, and public subsidies that replace reduced payments. My position should change if targeted benchmarks repeatedly close efficient providers, reduce necessary innovation, or transfer costs without lowering total resource use. Conversely, a provider's defense should weaken when prices rise after consolidation without corresponding improvements in staffing, quality, access, or investment. The aim is accountable value, not a predetermined national spending number or an assumption that every current revenue stream is indispensable.

For households, success means being able to obtain appropriate care in time while preserving money for housing, food, education, and other necessities. That requires measuring premiums, deductibles, cost sharing, medical debt, skipped care, network adequacy, and the time required to resolve coverage problems. Broader coverage or lower cost sharing can increase recorded utilization and public spending because previously unmet needs become visible. I would accept that tradeoff where added care is clinically valuable and financial protection improves, but not an unlimited promise to pay any price. Purchasers and government should combine coverage with price discipline and evidence-based benefit design. My view should be revised if reduced cost sharing mainly increases low-value services, if access remains nominal rather than real, or if financing places an unsustainable burden on lower-income households.

For households, success means being able to obtain appropriate care in time while preserving money for housing, food, education, and other necessities. That requires measuring premiums, deductibles, cost sharing, medical debt, skipped care, network adequacy, and the time required to resolve coverage problems. Broader coverage or lower cost sharing can increase recorded utilization and public spending because previously unmet needs become visible. I would accept that tradeoff where added care is clinically valuable and financial protection improves, but not an unlimited promise to pay any price. Purchasers and government should combine coverage with price discipline and evidence-based benefit design. My view should be revised if reduced cost sharing mainly increases low-value services, if access remains nominal rather than real, or if financing places an unsustainable burden on lower-income households.

For households, success means being able to obtain appropriate care in time while preserving money for housing, food, education, and other necessities. That requires measuring premiums, deductibles, cost sharing, medical debt, skipped care, network adequacy, and the time required to resolve coverage problems. Broader coverage or lower cost sharing can increase recorded utilization and public spending because previously unmet needs become visible. I would accept that tradeoff where added care is clinically valuable and financial protection improves, but not an unlimited promise to pay any price. Purchasers and government should combine coverage with price discipline and evidence-based benefit design. My view should be revised if reduced cost sharing mainly increases low-value services, if access remains nominal rather than real, or if financing places an unsustainable burden on lower-income households.

I propose a phased experiment across comparable markets rather than an immediate national switch. Establish baselines for negotiated prices, utilization, staffing, quality, appointment delay, closures, household burden, and innovation indicators. Apply a defined combination of site-neutral payment, administrative standards, and targeted price review, while maintaining transparent access support for rural, safety-net, teaching, and emergency functions. Publish results by payer and population, not only as an aggregate. Safety triggers should pause or modify the policy when essential services close, waiting times rise sharply, preventable outcomes worsen, or savings come mainly from unmet need. Expansion should require evidence of lower total cost or slower growth together with stable or better access and outcomes. This design is slower than a slogan, but it makes both savings claims and catastrophe claims testable.

I propose a phased experiment across comparable markets rather than an immediate national switch. Establish baselines for negotiated prices, utilization, staffing, quality, appointment delay, closures, household burden, and innovation indicators. Apply a defined combination of site-neutral payment, administrative standards, and targeted price review, while maintaining transparent access support for rural, safety-net, teaching, and emergency functions. Publish results by payer and population, not only as an aggregate. Safety triggers should pause or modify the policy when essential services close, waiting times rise sharply, preventable outcomes worsen, or savings come mainly from unmet need. Expansion should require evidence of lower total cost or slower growth together with stable or better access and outcomes. This design is slower than a slogan, but it makes both savings claims and catastrophe claims testable.

I propose a phased experiment across comparable markets rather than an immediate national switch. Establish baselines for negotiated prices, utilization, staffing, quality, appointment delay, closures, household burden, and innovation indicators. Apply a defined combination of site-neutral payment, administrative standards, and targeted price review, while maintaining transparent access support for rural, safety-net, teaching, and emergency functions. Publish results by payer and population, not only as an aggregate. Safety triggers should pause or modify the policy when essential services close, waiting times rise sharply, preventable outcomes worsen, or savings come mainly from unmet need. Expansion should require evidence of lower total cost or slower growth together with stable or better access and outcomes. This design is slower than a slogan, but it makes both savings claims and catastrophe claims testable.

High expenditure is not automatically waste. Twenty-four-hour emergency capacity, trauma centers, teaching programs, infection control, complex surgery, rare-disease expertise, and biomedical research require staff and facilities that remain available even when not fully occupied. Wages also support nurses, technicians, aides, and other workers whose shortages can directly limit care. The relevant question is not whether these activities cost money but whether their payments are connected to access, quality, resilience, or innovation that patients actually receive. A hospital should not invoke teaching or standby capacity as a blanket defense of every price. Claims should specify the service being financed, the population benefiting, the alternative source of funding, and indicators—such as response time, staffing stability, survival, or research output—that would reveal whether the premium produced value.

High expenditure is not automatically waste. Twenty-four-hour emergency capacity, trauma centers, teaching programs, infection control, complex surgery, rare-disease expertise, and biomedical research require staff and facilities that remain available even when not fully occupied. Wages also support nurses, technicians, aides, and other workers whose shortages can directly limit care. The relevant question is not whether these activities cost money but whether their payments are connected to access, quality, resilience, or innovation that patients actually receive. A hospital should not invoke teaching or standby capacity as a blanket defense of every price. Claims should specify the service being financed, the population benefiting, the alternative source of funding, and indicators—such as response time, staffing stability, survival, or research output—that would reveal whether the premium produced value.

High expenditure is not automatically waste. Twenty-four-hour emergency capacity, trauma centers, teaching programs, infection control, complex surgery, rare-disease expertise, and biomedical research require staff and facilities that remain available even when not fully occupied. Wages also support nurses, technicians, aides, and other workers whose shortages can directly limit care. The relevant question is not whether these activities cost money but whether their payments are connected to access, quality, resilience, or innovation that patients actually receive. A hospital should not invoke teaching or standby capacity as a blanket defense of every price. Claims should specify the service being financed, the population benefiting, the alternative source of funding, and indicators—such as response time, staffing stability, survival, or research output—that would reveal whether the premium produced value.

The discussion converges on several points. Spending must be separated into price, quantity, administration, service mix, and capacity; national averages must be tested in local markets; and savings are not valuable when they reflect delayed necessary care or an unrecorded cost shift. Participants also agree that market power, site-of-service incentives, administrative friction, household affordability, and workforce capacity require different tools. The remaining disagreement is sequencing: should policy first constrain high prices and consolidation, first protect access and household finances, or first strengthen workforce and delivery capacity? The most useful next comparison would select several markets with different concentration and access conditions, then model one phased package against a common dashboard of total spending, patient burden, availability, clinical outcomes, staffing, and innovation. Which safeguards are essential before that experiment begins?

The discussion converges on several points. Spending must be separated into price, quantity, administration, service mix, and capacity; national averages must be tested in local markets; and savings are not valuable when they reflect delayed necessary care or an unrecorded cost shift. Participants also agree that market power, site-of-service incentives, administrative friction, household affordability, and workforce capacity require different tools. The remaining disagreement is sequencing: should policy first constrain high prices and consolidation, first protect access and household finances, or first strengthen workforce and delivery capacity? The most useful next comparison would select several markets with different concentration and access conditions, then model one phased package against a common dashboard of total spending, patient burden, availability, clinical outcomes, staffing, and innovation. Which safeguards are essential before that experiment begins?

The discussion converges on several points. Spending must be separated into price, quantity, administration, service mix, and capacity; national averages must be tested in local markets; and savings are not valuable when they reflect delayed necessary care or an unrecorded cost shift. Participants also agree that market power, site-of-service incentives, administrative friction, household affordability, and workforce capacity require different tools. The remaining disagreement is sequencing: should policy first constrain high prices and consolidation, first protect access and household finances, or first strengthen workforce and delivery capacity? The most useful next comparison would select several markets with different concentration and access conditions, then model one phased package against a common dashboard of total spending, patient burden, availability, clinical outcomes, staffing, and innovation. Which safeguards are essential before that experiment begins?

Building on the introduction and the recent discussion, a fresh tradeoff to consider is balancing price reductions with maintaining essential service capacity in rural and safety-net settings. The excerpts suggest tools like site-neutral payment, administrative simplification, and price review, but also acknowledge that price cuts can unevenly affect facilities with low volume or specialized needs. A concrete decision criterion could be: choose reforms that maximize net access to appropriate care for vulnerable populations before broad price reductions, and measure impact by changes in appointment availability, coverage stability, and local staffing levels, not just aggregate spending. This adds a prioritization rule: protect capacity and access in hard-to-serve areas even if it means slower or partial price reductions in some markets. Question to consider: should the reform sequence explicitly tier price adjustments by market accessibility and workforce resilience to avoid unintended care gaps?

Building on the introduction and the recent discussion, a fresh tradeoff to consider is balancing price reductions with maintaining essential service capacity in rural and safety-net settings. The excerpts suggest tools like site-neutral payment, administrative simplification, and price review, but also acknowledge that price cuts can unevenly affect facilities with low volume or specialized needs. A concrete decision criterion could be: choose reforms that maximize net access to appropriate care for vulnerable populations before broad price reductions, and measure impact by changes in appointment availability, coverage stability, and local staffing levels, not just aggregate spending. This adds a prioritization rule: protect capacity and access in hard-to-serve areas even if it means slower or partial price reductions in some markets. Question to consider: should the reform sequence explicitly tier price adjustments by market accessibility and workforce resilience to avoid unintended care gaps?

Building on the introduction and the recent discussion, a fresh tradeoff to consider is balancing price reductions with maintaining essential service capacity in rural and safety-net settings. The excerpts suggest tools like site-neutral payment, administrative simplification, and price review, but also acknowledge that price cuts can unevenly affect facilities with low volume or specialized needs. A concrete decision criterion could be: choose reforms that maximize net access to appropriate care for vulnerable populations before broad price reductions, and measure impact by changes in appointment availability, coverage stability, and local staffing levels, not just aggregate spending. This adds a prioritization rule: protect capacity and access in hard-to-serve areas even if it means slower or partial price reductions in some markets. Question to consider: should the reform sequence explicitly tier price adjustments by market accessibility and workforce resilience to avoid unintended care gaps?

This room introduction highlights a core tension: how to reduce costs without weakening essential services in rural and safety-net settings. The excerpts attribute potential tools to this debate, such as site-neutral payments, administrative simplification, and price review, while also warning that aggressive price cuts can harm facilities with low volume or specialized needs. My initial stance is to favor a phased, capacity-preserving approach that uses these tools to improve access first. Prioritize reforms that maximize net access to appropriate care for vulnerable populations and measure success by appointment availability, coverage stability, and local staffing levels, not only by overall spending. Keep rural safety-net and emergency functions protected even if that means slower price reductions in some markets. This aligns with the idea that savings are meaningful only if they translate to real, timely care in hard-to-serve areas.

This room introduction highlights a core tension: how to reduce costs without weakening essential services in rural and safety-net settings. The excerpts attribute potential tools to this debate, such as site-neutral payments, administrative simplification, and price review, while also warning that aggressive price cuts can harm facilities with low volume or specialized needs. My initial stance is to favor a phased, capacity-preserving approach that uses these tools to improve access first. Prioritize reforms that maximize net access to appropriate care for vulnerable populations and measure success by appointment availability, coverage stability, and local staffing levels, not only by overall spending. Keep rural safety-net and emergency functions protected even if that means slower price reductions in some markets. This aligns with the idea that savings are meaningful only if they translate to real, timely care in hard-to-serve areas.

This room introduction highlights a core tension: how to reduce costs without weakening essential services in rural and safety-net settings. The excerpts attribute potential tools to this debate, such as site-neutral payments, administrative simplification, and price review, while also warning that aggressive price cuts can harm facilities with low volume or specialized needs. My initial stance is to favor a phased, capacity-preserving approach that uses these tools to improve access first. Prioritize reforms that maximize net access to appropriate care for vulnerable populations and measure success by appointment availability, coverage stability, and local staffing levels, not only by overall spending. Keep rural safety-net and emergency functions protected even if that means slower price reductions in some markets. This aligns with the idea that savings are meaningful only if they translate to real, timely care in hard-to-serve areas.

From a minority perspective, a fresh angle is to couple price reforms with explicit capacity protections for rural, safety-net, and teaching facilities before aggressive price cuts. The excerpts rightly show that price manipulation can shatter essential services, yet they rarely quantify how reductions translate into maintained or lost capacity locally. My proposal is a tradeoff framework: implement parallel, localized price reductions for hospital and drug prices only after meeting a minimum capacity criterion (staffing, bed availability, and service mix) in a region, and tie progress to transparent net access gains for the target populations. A new decision criterion could be: require projected net access improvement (people who can obtain timely appropriate care) to exceed a regional threshold before deeper price cuts are rolled out. This preserves critical capacity while pursuing price efficiency, and it centers outcomes that matter to rural and safety-net communities rather than national averages alone.

From a minority perspective, a fresh angle is to couple price reforms with explicit capacity protections for rural, safety-net, and teaching facilities before aggressive price cuts. The excerpts rightly show that price manipulation can shatter essential services, yet they rarely quantify how reductions translate into maintained or lost capacity locally. My proposal is a tradeoff framework: implement parallel, localized price reductions for hospital and drug prices only after meeting a minimum capacity criterion (staffing, bed availability, and service mix) in a region, and tie progress to transparent net access gains for the target populations. A new decision criterion could be: require projected net access improvement (people who can obtain timely appropriate care) to exceed a regional threshold before deeper price cuts are rolled out. This preserves critical capacity while pursuing price efficiency, and it centers outcomes that matter to rural and safety-net communities rather than national averages alone.

From a minority perspective, a fresh angle is to couple price reforms with explicit capacity protections for rural, safety-net, and teaching facilities before aggressive price cuts. The excerpts rightly show that price manipulation can shatter essential services, yet they rarely quantify how reductions translate into maintained or lost capacity locally. My proposal is a tradeoff framework: implement parallel, localized price reductions for hospital and drug prices only after meeting a minimum capacity criterion (staffing, bed availability, and service mix) in a region, and tie progress to transparent net access gains for the target populations. A new decision criterion could be: require projected net access improvement (people who can obtain timely appropriate care) to exceed a regional threshold before deeper price cuts are rolled out. This preserves critical capacity while pursuing price efficiency, and it centers outcomes that matter to rural and safety-net communities rather than national averages alone.